This content is generated by AI. You can give feedback on it in the Inderes forum.
Translation: Original published in Finnish on 11/18/2026 at 7:45 am EET.
Aiforia held an investor webinar on Tuesday, a recording of which is available here. In addition to CEO Jukka Tapaninen, the speakers included Angelo Paolo Dei Tos, Professor of Pathology at the University of Padua, and Katie Gillette Maloney, a Partner at the consulting firm DeciBio who specializes in digital pathology. The event provided interesting additional insight into the state of the customer base, hospital customers’ user experiences, and how far the market has developed.
Dei Tos said that the Veneto region, with a population of ~5 million, selected Aiforia through a competitive tender as the region’s shared digital pathology AI platform. The region processes ~3 million glass slides a year. The payer asked the region for a pilot study, and data has been collected for ~2 months. According to preliminary results, both pathologists’ working time and turnaround times for prostate biopsies have fallen by ~50%. The current contract formally ends at the turn of the year, but it will be extended by one year. The region is already preparing a new procurement for broader use of AI, and next year, the plan is to extend use to areas including HER2 analysis in breast cancer. As we understand it, the new procurement is open to competition, but we believe Aiforia’s position in it is very strong.
According to DeciBio’s Maloney, the global digital pathology market is ~1.2 BUSD this year, of which AI solutions still account for only a fairly small share. The market is estimated to grow by ~12% a year to 2.1 BUSD by 2031. About two-thirds of spending comes from pharmaceutical and CRO companies, while the clinical side accounts for roughly one-third. Roughly 30% of pathology laboratories in the US and the five largest EU countries have a scanner, but only ~10% diagnose digitally. AI or image analysis tools are used by ~25% of laboratories in Europe and ~5% in the US. The US reimbursement system is still incomplete, and DeciBio estimates that broader payment models will take another 3–5 years.
The figures support our view of the market’s long-term potential. Clinical growth in the coming years will rely on Europe and public payer initiatives. This fits Aiforia’s position well, as the company’s competitive advantage rests on a broad portfolio of CE-IVD-marked models. According to Maloney, end-to-end solutions from players such as Roche and Agilent make adoption easier for laboratories. In her view, these platforms could also expand the customer base of independent algorithm providers in the coming years.
For investors, the most important new information concerned the build-up of the customer base. Based on the webinar, Aiforia has over 20 clinical key accounts, seven of which are in production use. The solution has been delivered to some customers, but they have not yet started using it. Some customer accounts are still in the delivery phase. According to management, it typically takes 6–9 months for a contract to translate into revenue. Some contracts signed two years ago, however, are still not in use. This is due to the customers’ own scanner, laboratory information system, and image management projects. According to the company, active customers’ usage volumes have more than doubled since the start of the year.
The figures provide some visibility into the future, as delivered customer accounts and those in the delivery phase are the source of growth for the coming years. Based on the typical lag, contracts signed earlier in the year, such as those with AP-HP and in Spain, should start to show in revenue around the turn of the year. Our forecast for next year (revenue of 4.6 MEUR, +75%) requires a significant share of these customer accounts to move into production use.
According to Tapaninen, the company has a cash runway of ~12 months, which includes its current cash and part of the EIB loan. The 20 MEUR EIB loan is divided into three tranches (5, 7, and 8 MEUR). Drawing down the tranches requires meeting conditions tied to revenue and other milestones. Whether the funding is sufficient therefore depends on growth, as does the entire investment story. If later loan tranches cannot be drawn, additional financing may be needed as early as next year. The decisive factor remains how quickly signed contracts turn into revenue.
This content is only available for logged in users